{"id":9553,"date":"2023-09-06T18:21:37","date_gmt":"2023-09-06T18:21:37","guid":{"rendered":"https:\/\/www.yuhan-usa.com\/?p=9553"},"modified":"2023-09-07T13:55:09","modified_gmt":"2023-09-07T13:55:09","slug":"yuhan-yang-and-cyrus-therapeutics-joint-research-on-anti-cancer-target-therapeutics","status":"publish","type":"post","link":"https:\/\/www.yuhan-usa.com\/yuhan-yang-and-cyrus-therapeutics-joint-research-on-anti-cancer-target-therapeutics\/","title":{"rendered":"Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics\u00a0"},"content":{"rendered":"\n
Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy.<\/p>\n\n\n\n
Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells.<\/p>\n\n\n\n
Through the agreement, the two companies plan to cooperate in the fields of basic research on anti-cancer drug development, development of new anti-cancer drug candidates, technology transfer and commercialization using Cyrus Therapeutics’ technologies.<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n